Mersana Therapeutics to Present at 29th Annual Credit Suisse Virtual Healthcare Conference

Rhea-AI Summary

Mersana Therapeutics, Inc. (NASDAQ:MRSN) announced that CEO Anna Protopapas will present at the 29th Annual Credit Suisse Virtual Healthcare Conference on November 11 at 11:00 a.m. ET. A live webcast of the presentation can be accessed on Mersana’s website, with an archived replay available for 90 days. Mersana is focused on developing antibody-drug conjugates (ADCs) to address significant cancer treatment needs. Their lead candidate, XMT-1536, is in a Phase 1 clinical study for ovarian cancer, while XMT-1592 targets NaPi2b-expressing tumors.

CAMBRIDGE, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that Anna Protopapas, President and Chief Executive Officer, will present at the 29^th Annual Credit Suisse Virtual Healthcare Conference on Wednesday, November 11, at 11:00 a.m. ET.   

A live webcast of the presentation will be available on the Investors & Media section of Mersana’s website at www.mersana.com. An archived replay will be available for approximately 90 days following the presentation.

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, XMT-1536, is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early stage programs include a B7-H4 targeting ADC, as well as a STING agonist ADC developed using the Company’s Immunosynthen platform. In addition, multiple partners are using Mersana’s Dolaflexin platform to advance their ADC pipelines.

Contact:

Investor & Media Contact
Sarah Carmody
617-844-8577
scarmody@mersana.com

FAQ

What is the date of Mersana Therapeutics' presentation at the Credit Suisse Conference?

Mersana Therapeutics will present on November 11, 2020.

Who will present for Mersana Therapeutics at the Credit Suisse Virtual Healthcare Conference?

Anna Protopapas, the President and CEO, will be presenting.

Where can I watch the Mersana Therapeutics presentation?

The presentation can be viewed live on Mersana's website.

What is the focus of Mersana Therapeutics' research and products?

Mersana Therapeutics focuses on developing antibody-drug conjugates (ADCs) for cancer treatment.

Which clinical studies are Mersana Therapeutics currently conducting?

Mersana's lead product candidate, XMT-1536, is in a Phase 1 study for ovarian cancer, and XMT-1592 is also in Phase 1 targeting NaPi2b-expressing tumors.